Indications › Atrial fibrillation
GLP‑1 drugs in atrial fibrillation
Which incretin agents are being studied in atrial fibrillation, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 11
- Active
- 9
- Results scheduled
- 5
- Molecules studied
- 3
- Sponsors
- 10
No GLP‑1 or incretin drug is FDA-approved for atrial fibrillation. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for atrial fibrillation, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 10 of the 11 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 1 still in early phases. 10 distinct sponsors are involved.
Molecules studied in this indication
liraglutide · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2026-12-31 | tirzepatide | TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation NCT06802081 · The Cleveland Clinic | P2 | 100 |
| 2027-04-10 | semaglutide | DUTCH Weight Control in Atrial Fibrillation Study NCT06184633 · Rijnstate Hospital | P4 | 280 |
| 2027-12 | semaglutide | Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation NCT06499857 · University of Chicago | P3 | 200 |
| 2028-12-30 | semaglutide | Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study NCT07275697 · Emma Svennberg | P4 | 200 |
| 2029-04 | semaglutide | Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation NCT07389941 · University of Luebeck | P4 | 240 |
Trials on file
All 11 incretin trials recorded in this indication, active first.